Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases

Summary

This Phase 1 study is designed to assess the safety, tolerability, and schedule feasibility of administering Rhenium-186 NanoLiposome (REYOBIQ) at different dosing intervals following whole brain radiotherapy (WBRT) or proton craniospinal irradiation (PCSI).

Timeline

Start

2026-07

Primary completion

2028-07

Completion

2031-07

Drugs

Indications